The detailed analysis of the global neurostimulation device market shows that in terms of revenue, the market is estimated to grow at a CAGR of 10.23% during the forecasting years 2019-2027. The market is expected to generate a revenue of $11899.1 million by the year 2027. The implantable devices used for neuromodulation are referred to as neurostimulation devices or neurostimulators.

Report scope can be customized per your requirements. Request For Customization

Neurostimulation is a potential alternative for individuals unresponsive to drug therapy or surgeries. Neurostimulation devices help in the therapeutic activation of the nervous system. These implantable devices send electrical stimuli to the brain, spinal cord, and other organs, playing an integral function in the nervous system. The neurostimulator sends a target-specific stimulus that inhibits the passage of pain signals to the brain. Healthcare experts use these devices to treat various neurological disorders such as epilepsy, pain, depression, Parkinson’s disease, obsessive-compulsive disorder, dystonia, and tremor, which will likely boost the neurostimulation device market.

The study aims to get an overview of the neurostimulation device market in terms of various factors. Within this report, the market definition and the key insights regarding the neurostimulation device market have been discussed. Also, the value chain outlook, market trends, market share outlook, Pestle outlook, and market attractiveness index have been studied in detail.

Market drivers like the rising incidence of neuro diseases, increasing geriatric population, growing demand for MRI scans, and favorable reimbursement policies are driving the neurostimulation device market growth. However, the market is facing market restraints like the high cost of neuromodulation treatment and the presence of alternative therapy, which are obstructing the market growth.

Key opportunities like the high market potential for SCS devices in neurostimulation, technological development, and growing incidence of chronic discomfort can be leveraged by the market to reach the projected growth. However, challenges such as stringent regulatory approvals and side-effects of associated neurostimulation devices are being faced by this market.

To get detailed insights on segments, Download Sample Report



Geographies covered in the neurostimulation device market by region are:

• North America: The United States and Canada

• Asia-Pacific: China, Japan, India, South Korea, Australia & New Zealand, ASEAN countries and Rest of Asia-Pacific

• Europe: The United Kingdom, Germany, Italy, Russia, Spain, France and Rest of Europe

• Latin America: Brazil, Mexico and Rest of Latin America

• Middle East & Africa: Turkey, the United Arab Emirates, South Africa, Saudi Arabia, and the Rest of Middle East & Africa

The neurostimulation device market has been segmented as follows:

• By System

O Spinal cord stimulators

O Gastric electric stimulator

O Sacral nerve stimulators

O Deep brain stimulators

O Vagus nerve stimulators

O Other systems

• By Application

O Gastroparesis

O Pain management

O Depression

O Parkinson’s disease

O Epilepsy

O Essential tremor

O Urinary and fecal incontinence

O Dystonia

O Other applications

The key players engaged in the neurostimulation device market are Aleva Neurotherapeutics SA, Boston Scientific Corporation, Cogentix Medical, Inc., Cyberonics, Inc., DePuy Synthes Companies, Dr. Langer Medical GmbH, Ectron Limited, Ekso Bionics Holding Inc., Helius Medical Technologies, Hocoma AG, Medtronic plc, Neuronetics, Inc., Nevro Corp., St. Jude Medical, Inc. (acquired by Abbott Laboratories) and The Magstim Company Limited.

The strategic analysis for each of these companies has been covered in detail. The neurostimulation device market by company share helps to dive into the information about the key market players in this market and how much hold they have on the market.



